| Page 69 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes

Author(s): 
Reilly B, Tanaka TN, Diep D, Yeerna H, Tamayo P, Zhang K, Bejar R
Primary Author: 
Reilly B
Journal Title: 
Blood Advances
Original Publication Date: 
Oct 2019

Recurrent mutations implicate several epigenetic regulators in the early molecular pathobiology of

Bone Marrow Disease(s): 

The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion

Author(s): 
Park S, Kelaidi C, Meunier M, Casadevall N, Gerds AT, Platzbecker U
Primary Author: 
Park S
Journal Title: 
Annals of Hematology
Original Publication Date: 
Oct 2019

Bone Marrow Disease(s): 

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence

Author(s): 
Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP
Primary Author: 
Nazha A
Journal Title: 
JCO Precision Oncology
Original Publication Date: 
Sep 2019

PURPOSE:

Bone Marrow Disease(s): 

Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes

Author(s): 
Madan V, Li J, Zhou S, Teoh WW, Han L, Meggendorfer M, Malcovati L, Cazzola M, Ogawa S, Haferlach T, Yang H, Koeffler HP
Primary Author: 
Madan V
Journal Title: 
American Journal of Hematology
Original Publication Date: 
Nov 2019

Bone Marrow Disease(s): 

Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years

Author(s): 
Sheth VS, Potter V, Gandhi SA, Kulasekararaj AG, de Lavallade H, Muus P, Pagliuca A, Rice CFM, Mehra V, Grimaldi F, Inam S, Barber LD, Mufti GJ, Marsh JC
Primary Author: 
Sheth VS
Journal Title: 
Blood Advances
Original Publication Date: 
Oct 2019

Survival after allogeneic hematopoietic cell transplantation (HSCT) for severe

Bone Marrow Disease(s): 

Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia

Author(s): 
Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, Aljurf M, Badawy SM, Beitinjaneh A, Boelens JJ, Diaz MA, Dvorak CC, Gadalla S, Gajewski J, Gale RP, Ganguly S, Gennery AR, George B, Gergis U, Gómez-Almaguer D
Primary Author: 
Bejanyan N
Journal Title: 
Blood Advances
Original Publication Date: 
Oct 2019

Allogeneic bone marrow transplantation (BMT) is curative therapy for the treatment of patients with severe

Bone Marrow Disease(s): 

When Your Child With a Rare Disease Doesn’t Feel Brave

Have you ever done something that you knew was the right thing to do, but you were scared to do it? Or maybe you did something that looked hard, but you decided to try it. That is courage in action and you probably felt very good about what you did. And you should!

Courage shows up in many ways all around you. Courage is standing up for a friend, helping someone in need or sticking with something that is hard for you to do. They say that having courage makes you a better person, and courage is one of the most important faculties you can develop.